ULTRAGENYX PHARMACEUTICAL INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ULTRAGENYX PHARMACEUTICAL INC. stock issued during period, value, stock options exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.00M, a 80.00% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. stock issued during period, value, stock options exercised for fiscal 2023 was $5.00M, a 95.92% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. stock issued during period, value, stock options exercised for fiscal 2022 was $2.55M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-18 | |
| 2024-12-31 | $1.00M 10-K · filed 2026-02-18 | |
| 2023-12-31 | $5.00M 10-K · filed 2026-02-18 | |
| 2022-12-31 | $2.55M 10-K · filed 2025-02-19 | |
| 2016-12-31 | $9.10M 10-K · filed 2017-02-17 | |
| 2015-12-31 | $7.36M 10-K · filed 2017-02-17 | |
| 2014-12-31 | $736.00K 10-K · filed 2017-02-17 | |
| 2013-12-31 | $171.00K 10-K · filed 2016-02-26 | |
| 2012-12-31 | $131.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |